| 000 | 01616 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513112532.0 | ||
| 264 | 0 | _c19970501 | |
| 008 | 199705s 0 0 eng d | ||
| 022 | _a0090-466X | ||
| 024 | 7 |
_a10.1007/BF02353515 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMummaneni, V | |
| 245 | 0 | 0 |
_aBioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters. _h[electronic resource] |
| 260 |
_bJournal of pharmacokinetics and biopharmaceutics _cAug 1996 |
||
| 300 |
_a313-25 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacokinetics |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aEtoposide _xanalogs & derivatives |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOrganophosphorus Compounds _xpharmacokinetics |
| 650 | 0 | 4 |
_aProdrugs _xpharmacokinetics |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 700 | 1 | _aKaul, S | |
| 700 | 1 | _aIgwemezie, L N | |
| 700 | 1 | _aNewell, D R | |
| 700 | 1 | _aPorter, D | |
| 700 | 1 | _aThomas, H | |
| 700 | 1 | _aCalvert, A H | |
| 700 | 1 | _aWinograd, B | |
| 700 | 1 | _aBarbhaiya, R H | |
| 773 | 0 |
_tJournal of pharmacokinetics and biopharmaceutics _gvol. 24 _gno. 4 _gp. 313-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF02353515 _zAvailable from publisher's website |
| 999 |
_c9032671 _d9032671 |
||